# A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

> **NCT04777201** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1036 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Faricimab
- **OTHER:** Sham Procedure
- **DRUG:** Anti-VEGF Therapy

## Key facts

- **NCT ID:** NCT04777201
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-19
- **Primary completion:** 2024-09-03
- **Final completion:** 2024-09-03
- **Target enrollment:** 1036 (ACTUAL)
- **Last updated:** 2025-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777201, "A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04777201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*